Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review

• Published in: Thrombosis journal Vol. 19; no. 1; pp. 54 - 16
• Main Authors: Ockerman, Anna, Vanassche, Thomas, Garip, Melisa, Vandenbriele, Christophe, Engelen, Matthias M, Martens, Jeroen, Politis, Constantinus, Jacobs, Reinhilde, Verhamme, Peter
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.08.2021; BioMed Central; BMC
• Subjects: Acids; Antifibrinolytic agents; Aprotinin; Blood diseases; Brain; Care and treatment; Clinical trials; Database searching; Disease prevention; Drug dosages; Elective surgery; Epistaxis; Health aspects; Heart surgery; Hemophilia; Hemorrhage; Injuries; Internet/Web search services; Medicin och hälsovetenskap; Menstruation; Mortality; Online searching; Prevention; Review; Rhinoplasty; Tranexamic acid; Transplantation of organs, tissues, etc
• ISSN: 1477-9560; 1477-9560
• DOI: 10.1186/s12959-021-00303-9

We review the evidence for tranexamic acid (TXA) for the treatment and prevention of bleeding caused by surgery, trauma and bleeding disorders. We highlight therapeutic areas where evidence is lacking and discuss safety issues, particularly the concern regarding thrombotic complications. An electronic search was performed in PubMed and the Cochrane Library to identify clinical trials, safety reports and review articles. TXA reduces bleeding in patients with menorrhagia, and in patients undergoing caesarian section, myomectomy, hysterectomy, orthopedic surgery, cardiac surgery, orthognathic surgery, rhinoplasty, and prostate surgery. For dental extractions in patients with bleeding disorders or taking antithrombotic drugs, as well as in cases of idiopathic epistaxis, tonsillectomy, liver transplantation and resection, nephrolithotomy, skin cancer surgery, burn wounds and skin grafting, there is moderate evidence that TXA is effective for reducing bleeding. TXA was not effective in reducing bleeding in traumatic brain injury and upper and lower gastrointestinal bleeding. TXA reduces mortality in patients suffering from trauma and postpartum hemorrhage. For many of these indications, there is no consensus about the optimal TXA dose. With certain dosages and with certain indications TXA can cause harm, such as an increased risk of seizures after high TXA doses with brain injury and cardiac surgery, and an increased mortality after delayed administration of TXA for trauma events or postpartum hemorrhage. Whereas most trials did not signal an increased risk for thrombotic events, some trials reported an increased rate of thrombotic complications with the use of TXA for gastro-intestinal bleeding and trauma. TXA has well-documented beneficial effects in many clinical indications. Identifying these indications and the optimal dose and timing to minimize risk of seizures or thromboembolic events is work in progress.